Edesa Biotech, Inc.
Edesa Biotech, Inc.
Your view on EDSA
Overview
What the company does, where it operates, and who runs it.
About Edesa Biotech, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Pardeep Nijhawan FRCPC,
- Headquarters
- 100 Spy Court, Markham, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Pardeep Nijhawan FRCPC,
- Headquarters
- 100 Spy Court, Markham, ON, CA
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis.
It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Edesa Biotech, Inc., and the rating behind it. EDSA last traded at $4.23; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Edesa Biotech, Inc.. Starting points for Edesa Biotech, Inc.: EPS -$1.57, beta 1.06 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Edesa Biotech, Inc.. Edesa Biotech, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Edesa Biotech, Inc.. Trailing twelve-month EPS for Edesa Biotech, Inc. stands at -$1.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Edesa Biotech, Inc.. Edesa Biotech, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Edesa Biotech, Inc. valued side by side against its closest peers. Edesa Biotech, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Edesa Biotech, Inc., and how their positions are changing. At a $40.7M market value, institutional positions materially move Edesa Biotech, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Edesa Biotech, Inc. executives and directors. Shares of Edesa Biotech, Inc. have traded between $1.55 and $4.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Edesa Biotech, Inc.. Edesa Biotech, Inc. is a $40.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Edesa Biotech, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Edesa Biotech, Inc.. Coverage tracks Edesa Biotech, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.